2026-10-13T18:30:53Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34026700 2026-09-29T17:37:18Z category_7 category_13 category_19 category_46 category_64 category_122 portal_5 item_type_1 month_year_09_2026

<p>Subgroup analysis: mortality hazard ratio.</p> Po-Huang Chen (8374326) Ming-Shen Dai (835570) Mao-Hsuan Huang (17475456) Hsin-Yu Chen (2165956) Li-Ting Kao (409065) Tina Yi-Jin Hsieh (22887737) Hong-Jie Jhou (9376258) Cho-Hao Lee (4114723) Medicine Genetics Pharmacology Immunology Cancer Mental Health showed null associations related adverse events propensity score matching prior 365 days preceding 90 days level pattern matched groups may differ everyday functional ability enhancing antitumor immunity cd8 +&# 8201 cancer genome atlas 20 cancer types first ici administration 008 ), driven cannot localize slc6a4 272 tumor samples year overall survival target trial emulation bzd prescription overlapping >- value 2 134 matched patients slc6a4 expression related immune checkpoint blockade users among patients hr range 0 target trial slc6a4 expression immune checkpoint tumor immune ssri users among 3 solid tumor composite immune xlink "> versus 34 thyroid dysfunction starting within ssri use ssri repurposing ssri group solid tumors serotonin transporter residual confounding psychiatric comorbidity primary outcome performance status <p>Forest plot of hazard ratios with 95% CIs for SSRI versus BZD across prespecified subgroups including age, sex, race, cancer type, metastatic status, psychiatric diagnosis type, ICI class, BMI, and individual SSRI agents (fluvoxamine omitted from the individual-agent panel owing to fewer than 10 users). The association with lower mortality was consistent across most subgroups. The association was strongest among patients with comorbid depression and anxiety (HR 0.57; 95% CI [0.49, 0.68]). All 5 individually analyzable SSRIs were associated with significantly lower mortality (HR range 0.61 to 0.71). Head and neck cancer was the only subgroup in which the estimate did not favor SSRI use (HR 1.08; 95% CI [0.69, 1.68]; <i>p</i> = 0.736). Hazard ratios are from Cox proportional hazards models fitted within each subgroup; <i>p</i> values are from log-rank tests.</p> <p>(TIF)</p> 2026-09-29T18:01:32Z Image Figure 10.1371/journal.pmed.1005262.s005 https://figshare.com/articles/figure/_p_Subgroup_analysis_mortality_hazard_ratio_p_/34026700 CC BY 4.0